This article describes a number-based system for the classification of insulin regimes. 
INTRODUCTION
The term ''taxonomy'' is used to describe the classification of various things, so the term ''drug taxonomy'' refers to the science of listing and describing drugs, according to various properties, in a manner which allows easy comprehension and understanding of their usage.
Traditionally, only pharmaceutical properties (e.g., chemical structure and pharmacodynamic and pharmacokinetic characteristics) have been used to separate drugs into various groups. Increasingly, however, the end user (i.e., the patient's or community's perspective) is considered when studying pharmacology [1, 2] . In the present work, we provide a balanced, syncretic approach to insulin taxonomy, using both patient-centered and pharmacokinetic aspects, to craft a number-based classification of insulin regimes.
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
CURRENT INSULIN TAXONOMY
Endocrinology and diabetology textbooks provide comprehensive coverage of various insulin preparations and then utilize these to discuss different insulin regimes. The current American Diabetes Association (ADA)/European Association for Study of Diabetes (EASD) 2015 guidelines use the terms ''basal,'' ''basal plus,'' ''premixed,'' ''split-mix,'' and ''intensive'' to describe insulin regimes [3] . Other terms used for regimes involving 3 or more injections per day are ''multiple'' and ''intensified'' insulin therapy. This drug-centered or pharmaceutical-based terminology served diabetology practitioners adequately in the past; the corresponding taxonomic methodology was able to incorporate the limited insulin preparations available, which included both traditional and modern insulins.
This pharmaceutical classification of insulin regimes is not, however, syntaxic with the current emphasis on a patient-centered approach. It must be reemphasized here that it is patient-centeredness which forms the basis for recent advances in drug development and improvements in treatment guidelines.
PATIENT-CENTERED INSULIN TAXONOMY
Most patients of diabetes do not appreciate the pharmacodynamic or kinetic nuances of insulin preparations. What is more relevant to the person requiring insulin is the number of injections to be taken per day, the timing of administration, and the flexibility with which these timings can be adjusted. Based upon these factors, it is important to craft a fresh synopsis of insulin regimes, using the number of injections per day as the framework for systematic study. At the same time, such a classification system must address the nature of insulin preparations, whether basal, premixed, or prandial.
Modern clinical trials are available which support the use of premixed insulin in once-daily and thrice-daily dosages, as opposed to the traditional twice-daily regime.
The basal insulins detemir and glargine often need to be prescribed twice daily in order to achieve adequate glycemic control. Innovative regimes utilizing combinations of rapid-acting and premixed/coformulated insulins with varying frequencies of administration have also been documented. These factors also provide important reasons to revisit current classifications of insulin preparations.
NUMBER-BASED CLASSIFICATION OF INSULIN REGIMES
While a number-based terminology has already been proposed [4] , it is inadequate to cover the current range of insulin preparations and the large number of regimens that they are used in.
With the newer insulin analogues available, a modern, number-based classification is required. 
